Medications and their effects on sleep.

[1]  J. Montplaisir,et al.  A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. , 2004, Sleep.

[2]  E. Laska,et al.  Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. , 2003, Sleep.

[3]  J. Pagel,et al.  Drug induced nightmares—an etiology based review , 2003, Human psychopharmacology.

[4]  B. Parnes,et al.  Medications for the Treatment of Sleep Disorders: An Overview. , 2001, Primary care companion to the Journal of clinical psychiatry.

[5]  E. van Cauter,et al.  A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westward jet lag. , 2000, Sleep.

[6]  B. Stone,et al.  Hypnotic activity of melatonin. , 2000, Sleep.

[7]  R. Chervin,et al.  Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. , 2000, Chest.

[8]  Pagel Jf.  Nightmares and disorders of dreaming. , 2000 .

[9]  E. Ernst,et al.  Valerian for insomnia: a systematic review of randomized clinical trials. , 2000, Sleep medicine.

[10]  John R Bloomfield,et al.  Effects of Fexofenadine, Diphenhydramine, and Alcohol on Driving Performance , 2000, Annals of Internal Medicine.

[11]  P. Hauri,et al.  Evaluation of chronic insomnia , 2000 .

[12]  K. Doghramji.  The need for flexibility in dosing of hypnotic agents. , 2000, Sleep.

[13]  G. Richardson.  Managing insomnia in the primary care setting: raising the issues. , 2000, Sleep.

[14]  M. Mitler.  Nonselective and selective benzodiazepine receptor agonists--where are we today? , 2000, Sleep.

[15]  C. George.  Perspectives on the management of insomnia in patients with chronic respiratory disorders. , 2000, Sleep.

[16]  S. Ancoli-Israel.  Insomnia in the elderly: a review for the primary care practitioner. , 2000, Sleep.

[17]  D. Skene,et al.  Complex effects of melatonin: evidence for photoperiodic responses in humans? , 1999, Sleep.

[18]  A. Vermeeren,et al.  Residual effects of evening and middle‐of‐the‐night administration of zaleplon 10 and 20 mg on memory and actual driving performance , 1998 .

[19]  G. Salkeld,et al.  Erratum to: Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy , 1998 .

[20]  E. Settle.  Antidepressant drugs: disturbing and potentially dangerous adverse effects. , 1998, The Journal of clinical psychiatry.

[21]  K. Mcclellan,et al.  Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy. , 1998, CNS drugs.

[22]  J. Fry.  Current issues in the diagnosis and management of narcolepsy , 1998, Neurology.

[23]  J. Pagel.  Pharmacological alteration of sleep and dreams — a clinical framework for utilizing the electrophysiological and sleep stage effects of psychoactive medications , 1996 .

[24]  M. Kryger,et al.  L-DOPA/carbidopa for nocturnal movement disorders in uremia. , 1996, Sleep.

[25]  T. Roth,et al.  Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young Adults , 1996, Biological Psychiatry.

[26]  M. Mahowald,et al.  Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. , 1996, The American journal of medicine.

[27]  R. Allen,et al.  Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. , 1996, Sleep.

[28]  Christopher Earley,et al.  Toward a better definition of the restless legs syndrome , 1995, Movement disorders : official journal of the Movement Disorder Society.

[29]  H. Volz,et al.  Antidepressant Drugs and Psychomotor Performance , 1995 .

[30]  J F O'Hanlon,et al.  Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989‐94 , 1995, Allergy.

[31]  G. Lavigne,et al.  Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. , 1994, Sleep.

[32]  C. Clary,et al.  Nefazodone and Imipramine in Major Depression: A Placebo-Controlled Trial , 1994, British Journal of Psychiatry.

[33]  R. Kessler,et al.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.

[34]  M. Danhof,et al.  Electroencephalogram Effect Measures and Relationships Between Pharmacokinetics and Pharmacodynamics of Centrally Acting Drugs , 1992, Clinical pharmacokinetics.

[35]  D. Greenblatt.  Benzodiazepine hypnotics: sorting the pharmacokinetic facts. , 1991, The Journal of clinical psychiatry.

[36]  T. Monk.  Sleep, sleepiness, and performance , 1991 .

[37]  W A Ray,et al.  Benzodiazepines of long and short elimination half-life and the risk of hip fracture. , 1989, JAMA.

[38]  M. Aldrich.  Automobile accidents in patients with sleep disorders. , 1989, Sleep.

[39]  F. W. Brown,et al.  Effects on sleep: a double-blind study comparing trimipramine to imipramine in depressed insomniac patients. , 1989, Sleep.

[40]  H. Babigian,et al.  Epidemiology of psychiatric disorders , 1989 .

[41]  G. Klauber,et al.  Clinical efficacy and safety of desmopressin in the treatment of nocturnal enuresis. , 1989, The Journal of pediatrics.

[42]  M. Kryger,et al.  Principles and Practice of Sleep Medicine , 1989 .

[43]  R. Godbout,et al.  The Treatment of the Restless Legs Syndrome with Clonazepam: A Prospective Controlled Study , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[44]  W. Herrmann.  Electroencephalography in drug research , 1982 .

[45]  T. Itil.  The discovery of psychotropic drugs by computer‐analyzed cerebral bioelectrical potentials (CEEG) , 1981 .

[46]  Pagel Jf.  Treatment of insomnia. , 1994, British medical journal.

[47]  R. D. Rudolf.  THE TREATMENT OF INSOMNIA * , 1922, British medical journal.